CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Therapeutic targeting of CDK7 has proven beneficial in preclinical studies, yet the off-target effects of currently available CDK7 inhibitors make it difficult to pinpoint the exact mechanisms behind MM cell death mediated by CDK7 inhibition. Here, we show that CDK7 expression positively correlates...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Yao, Ng, Jessica Fong, Park, Woojun Daniel, Samur, Mehmet, Morelli, Eugenio, Encinas Mayoral, Jessica, Chyra, Zuzana, Xu, Yan, Derebail, Sanika, Epstein, Charles, Nabet, Behnam, Chesi, Marta, Gray, Nathanael S., Young, Richard A., Kwiatkowski, Nicholas, Mitsiades, Constantine, Anderson, Kenneth C., Lin, Charles Y., Munshi, Nikhil C., Fulciniti, Mariateresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315622/
https://www.ncbi.nlm.nih.gov/pubmed/36877894
http://dx.doi.org/10.1182/blood.2022018885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315622/
https://www.ncbi.nlm.nih.gov/pubmed/36877894
http://dx.doi.org/10.1182/blood.2022018885

Ejemplares similares